上海预防医学2025，Vol.37Issue(8)：676-681,6.DOI:10.19428/j.cnki.sjpm.2025.24877
2022-2024年云南省德宏州应用直接抗病毒药物联合方案治疗不同基因型丙型肝炎的疗效
Efficacy of direct-acting antiviral agents combined regimens for hepatitis C virus with different genotypes in Dehong Prefecture,Yunnan Province from 2022 to 2024
摘要
Abstract
[Objective]To investigate the therapeutic effects of direct-acting antiviral agents(DAAs)combined regimens for hepatitis C virus(HCV)patients in Dehong Prefecture,Yunnan Province from 2022 to 2024,to analyze the characteristics of treatment failure patients,so as to provide a basis for discovering more effective treatment regimens in the future.[Methods]Data on HCV prevention and treatment in Dehong Prefecture was extracted from the China Disease Control and Prevention Information System.A total of 617 patients with HCV antiviral therapy were included,and the differences in variable characteristics among patients with different genotypes were analyzed using comparative statistical tests,including basic socio-demographic characteristics,biochemical testing indicators,and information on previous treatment and current treatment.In addition,the cure rate of HCV patients with diverse characteristics was compared,and the potential causes of treatment failure were explored simultaneously.[Results]The cure rate of HCV was 96.8%,and statistically significant differences were observed in aspartate transaminase(AST)and alanine transaminase(ALT)levels,previous antiviral therapy history and initial treatment regimens among patients with different HCV genotypes(all P<0.05).Among the multi-type combination regimens,the cure rate of sofosbuvir(SOF)-containing regimens was 97.00%,that of velpatasvir(VEL)-containing regimens was 95.45%,and the cure rate of other treatment regimens,including the regimens with ribavirin(RIB)intervention,was 93.10%.Among the patients with treatment failure,45.00%had genotype 3,40.00%had abnormal abdominal ultrasound results,and all presented with elevated baseline AST test levels.[Conclusion]The clinical treatment of HCV patients should consider the differences in genotype and biochemical test results.DAAs combined regimens for HCV have achieved a high cure rate in Dehong Prefecture and are applicable to HCV patients with diverse clinical characteristics,providing research evidence for wider application.关键词
丙型肝炎/基因型/用药方案/直接抗病毒药物/疗效Key words
hepatitis C virus/genotype/medication regimen/direct-acting antiviral agent/efficacy分类
医药卫生引用本文复制引用
唐仁海,丁盈盈,段松,赵艺丹,杨跃诚,叶润华,项丽芬,冯兴美,周群博,曹艳芬,何纳..2022-2024年云南省德宏州应用直接抗病毒药物联合方案治疗不同基因型丙型肝炎的疗效[J].上海预防医学,2025,37(8):676-681,6.基金项目
国家科技重大专项课题(2018ZX10721102-004) （2018ZX10721102-004）
